Data and safety monitoring policy for National Institute of Allergy and Infectious Diseases clinical trials

Clinical Trials

Volumn 8, Issue 6, 2011, Pages 727-735

  Dixon, Dennis O ^a   Weiss, Susanna ^a   Cahill, Kelly ^a   Fox, Lawrence ^a   Love, Joni ^a   McNamara, James ^a   Soto Torres, Lydia E ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCESS TO INFORMATION; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); DATA AND SAFETY MONITORING; HUMAN; MANAGEMENT; MONITORING; MOTIVATION; NATIONAL HEALTH ORGANIZATION; ORGANIZATIONAL STRUCTURE; PATIENT SAFETY; POLICY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RESPONSIBILITY;

CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS DATA MONITORING COMMITTEES; COMPUTER SECURITY; EFFICIENCY, ORGANIZATIONAL; HUMANS; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (U.S.); ORGANIZATIONAL POLICY; POLICY MAKING; SAFETY MANAGEMENT; UNITED STATES;

EID: 83455169023     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774511425181     Document Type: Article

References (22)

1. National Institute of Allergy and Infectious Diseases. Policy on Data and Safety Monitoring Board (DSMB) Operations. Version 3.0; release date 18 June 2009; effective date 2 July 2009. Available at http://www.niaid.nih.gov/ labsandresources/resources/toolkit/guidance/Pages/guidance.aspx and http://www.niaid.nih.gov/LabsAndResources/resources/toolkit/Documents/ dsmbpolicyv3.pdf.
2. Control Clin Trials. 1988 ; 9: 137-48
3. Ellenberg SS, Fleming TR, DeMets DL Data Monitoring Committees in Clinical Trials: A Practical Perspective. West Sussex: John Wiley & Sons ; 2002 :
4. Data Monitoring in Clinical Trials: A Case Study Approach. DeMets DL Furberg CD Friedman LM, ed. New York: Springer Science & Business Media, Inc. ; 2006 :
5. Herson J Data and Safety Monitoring in Clinical Trials. Taylor & Francis Group, LLC, Boca Raton, FL ; 2009 :
6. Grant AM, Altman DG, Babiker AB, et al. Issues in data monitoring and interim analysis of trials. Health Technol Assess. 2005 ; 9 (7). 1-238
7. Sydes MR, Spiegelhalter DJ, Altman DG, et al. Systematic qualitative review of the literature on data monitoring committees for randomized controlled trials. Clin Trials. 2004 ; 1 (1). 60-79
8. Sydes MR, Altman DG, Babiker AB, et al. Reported use of data monitoring committees in the main published reports of randomized controlled trials: a cross-sectional study. Clin Trials. 2004 ; 1 (1). 48-59
9. Clemens F, Elbourne D, Darbyshire J, et al. Data monitoring in randomized controlled trials: surveys of recent practice and policies. Clin Trials. 2005 ; 2 (1). 22-33 (Pubitemid 40332925)
10. US Food and Drug Administration. Guidance for Clinical Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees, updated March2006, Available at http://www.fda.gov/RegulatoryInformation/ Guidances/ucm127069.htm (accessed 28 March 2011).
11. US National Institutes of Health. Further Guidance on Data and Safety Monitoring for Phase I and II Trials, OD-00-038, June 5, 2000. Available at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-038.html and http://grants.nih.gov/grants/policy/hs/data-safety.htm (accessed 28 March 2011).
12. US National Institutes of Health. NIH Policy for Data and Safety Monitoring, 10June1998. Available at http://grants1.nih.gov/grants/guide/notice- files/not98-084.html (accessed 28 March 2011).
13. Cooperative Studies Program: Guidelines for the Planning and Conduct of Cooperative Studies. Washington, DC: Office of Research and Development ; 2001 :
14. International Conference on Harmonisation. Guideline for Industry-E3 Structure and Content of Clinical Study Reports (ICH July 1996). Available at http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines. html (accessed 28 March 2011).
15. International Conference on Harmonisation. Guidance for Industry-E6 Good Clinical Practice: Consolidated Guidance (ICH April 1996). Available at http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines. html (accessed 28 March 2011).
16. International Conference on Harmonisation. Guidance for Industry-E9 Statistical Principles for Clinical Trials (ICH September 1998). Available at http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines. html (accessed 28 March 2011).
17. International Conference on Harmonisation. E2A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. Available at http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines. html (accessed 28 March 2011).
18. International Conference on Harmonisation. E2B(R) ICH Harmonised Tripartite Guideline-Revision of the ICH Guideline on Clinical Safety Data Management: Data Elements for Transmission of Individual Case Safety Reports. Version 2.0.12May2005. Available at http://www.ich.org/products/guidelines/ efficacy/article/efficacy-guidelines.html (accessed 28 March 2011).
19. Council for International Organizations of Medical Sciences (CIOMS), in collaboration with the World Health Organization (WHO)Geneva, Switzerland: International Ethical Guidelines for Biomedical Research Involving Human Subjects, 2002(ISBN 92 9036 075 5). Available at http://www.cioms.ch/ publications/layout-guide2002.pdf (accessed 28 March 2011).
20. Draft Policy on Intramural Independent Safety Monitors
21. Ellenberg SS, Myers MW, Blackwelder WC, Hoth DF. The use of external monitoring committees in clinical trials of the National Institute of Allergy and Infectious Diseases. Stat Med. 1993 ; 12 (5/6). 461-7 (Pubitemid 23119063)
22. Grant AM, Altman DG, et al. A proposed charter for clinical trial data monitoring committees: helping them to do their job well. Lancet. 2005 ; 365 (9460). 711-22